45.03
0.63%
+0.28
After Hours:
45.03
Merus N.V stock is currently priced at $45.03, with a 24-hour trading volume of 703.06K.
It has seen a +0.63% increased in the last 24 hours and a -7.54% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $44.67 pivot point. If it approaches the $45.23 resistance level, significant changes may occur.
Merus N.V Stock (MRUS) Financials Data
Merus N.V (MRUS) Revenue 2023
MRUS reported a revenue (TTM) of $43.95 million for the quarter ending December 31, 2023, a +5.68% rise year-over-year.
Merus N.V (MRUS) Net Income 2023
MRUS net income (TTM) was -$154.94 million for the quarter ending December 31, 2023, a -18.10% decrease year-over-year.
Merus N.V (MRUS) Cash Flow 2023
MRUS recorded a free cash flow (TTM) of -$146.19 million for the quarter ending December 31, 2023, a +7.20% increase year-over-year.
Merus N.V (MRUS) Earnings per Share 2023
MRUS earnings per share (TTM) was -$3.04 for the quarter ending December 31, 2023, a -4.83% decline year-over-year.
Merus N.V Stock (MRUS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
Shuman Harry | VP Controller, PAO |
Dec 08 '23 |
Sale |
24.44 |
250 |
6,110 |
7,117 |
Shuman Harry | VP Controller, PAO |
Dec 01 '23 |
Option Exercise |
0.00 |
2,500 |
0 |
7,942 |
Shuman Harry | VP Controller, PAO |
Dec 01 '23 |
Sale |
24.58 |
575 |
14,133 |
7,367 |
Shuman Harry | VP Controller, PAO |
Jun 01 '23 |
Option Exercise |
0.00 |
2,500 |
0 |
6,017 |
Shuman Harry | VP Controller, PAO |
Jun 01 '23 |
Sale |
21.48 |
575 |
12,351 |
5,442 |
Iwicki Mark T | Director |
Apr 14 '23 |
Option Exercise |
7.27 |
73,576 |
534,679 |
73,576 |
Liu Hui | EVP, CBO & Head of Merus US |
Apr 06 '23 |
Option Exercise |
7.86 |
98,085 |
770,948 |
156,016 |
Merus N.V Stock (MRUS) Latest News
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Zacks Investment Research
Merus kündigt die Veröffentlichung eines Abstracts für die Präsentation auf der Jahrestagung 2024 der AACR an: Zeno hat sich in Krebsmodellen mit hoher NRG1-Expression als wirksam erwiesen
GlobeNewswire Inc.
Merus annonce ses résultats financiers pour le quatrième trimestre 2023 ainsi que pour l’ensemble de l’exercice 2023 et fait le point sur ses activités
GlobeNewswire Inc.
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
GlobeNewswire Inc.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Merus nimmt an bevorstehenden Investorenkonferenzen teil
GlobeNewswire Inc.
About Merus N.V
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Cap:
|
Volume (24h):